Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fibrinolysis and its current usage.

R N Rubin

    Clinical Therapeutics
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Fibrinolytic agents like streptokinase and urokinase dissolve blood clots. Urokinase is preferred for repeat treatments due to its non-antigenic nature, unlike streptokinase.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Feasibility and pharmacokinetics of carbamazepine oral loading doses.

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1998
    Same author

    Techniques for evaluating the cause of bleeding in the ICU. Diagnostic clues and keys to interpreting hemostatic tests.

    The Journal of critical illness·1995
    Same author

    Factor XI deficiency and hemostasis.

    American journal of hematology·1994
    Same author

    Refractory thrombocytopenia in a 27-year-old female following allogeneic bone marrow transplantation.

    American journal of hematology·1993
    Same author

    Platelet bleeding disorder in a 30-year-old female. Mechanisms of congenital platelet function defects.

    American journal of hematology·1993
    Same author

    Warfarin skin necrosis in a 33-year-old woman.

    American journal of hematology·1993
    Same journal

    Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

    Clinical therapeutics·2026
    Same journal

    Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

    Clinical therapeutics·2026
    Same journal

    Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

    Clinical therapeutics·2026
    Same journal

    Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

    Clinical therapeutics·2026
    Same journal

    Diversity: A Medical Research Imperative.

    Clinical therapeutics·2026
    Same journal

    LOARGYS (pegzilarginase-nbln).

    Clinical therapeutics·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Pharmacology
    • Cardiovascular Medicine

    Background:

    • Fibrinolytic agents activate plasminogen to plasmin, dissolving pathological thrombi.
    • Streptokinase, a bacterial fibrinolytic, is antigenic and can cause allergic reactions.
    • Urokinase, derived from human sources, is non-antigenic, allowing for repeated use.

    Purpose of the Study:

    • To compare the properties and applications of streptokinase and urokinase.
    • To outline the indications and contraindications for fibrinolytic therapy.
    • To describe methods for monitoring thrombolytic therapy.

    Main Methods:

    • Systemic (intravenous) and local (catheter) administration routes discussed.
    • Therapeutic applications for deep-vein thrombosis, pulmonary embolism, and myocardial infarction detailed.

    Related Experiment Videos

  • Contraindications including bleeding disorders and hypertension highlighted.

    • Main Results:

    • Urokinase offers an advantage over streptokinase for retreatment due to its non-antigenic profile.
    • Both agents are effective for systemic and local thrombolysis.
    • Monitoring via fibrinogen levels, degradation products, or thrombin time is crucial.

    Conclusions:

    • Fibrinolytic therapy is a key treatment for various thrombotic conditions.
    • Urokinase presents a safer alternative for patients requiring repeated thrombolytic interventions.
    • Careful patient selection and monitoring are essential for effective and safe fibrinolysis.